Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination.
Matusali G, Petruccioli E, Cimini E, Colavita F, Bettini A, Tartaglia E, Sbarra S, Meschi S, Lapa D, Francalancia M, Bordi L, Mazzotta V, Coen S, Mizzoni K, Beccacece A, Nicastri E, Pierelli L, Antinori A, Girardi E, Vaia F, Sette A, Grifoni A, Goletti D, Puro V, Maggi F. Matusali G, et al. Among authors: francalancia m. Vaccines (Basel). 2023 Sep 28;11(10):1541. doi: 10.3390/vaccines11101541. Vaccines (Basel). 2023. PMID: 37896943 Free PMC article.
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals.
Lapa D, Grousova DM, Matusali G, Meschi S, Colavita F, Bettini A, Gramigna G, Francalancia M, Garbuglia AR, Girardi E, Puro V, Antinori A, Kovyrshina AV, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Gushchin VA, Logunov DY, Naroditsky BS, Vaia F, Gintsburg AL. Lapa D, et al. Among authors: francalancia m. Vaccines (Basel). 2022 May 21;10(5):817. doi: 10.3390/vaccines10050817. Vaccines (Basel). 2022. PMID: 35632574 Free PMC article.
Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
Tortorella C, Aiello A, Gasperini C, Agrati C, Castilletti C, Ruggieri S, Meschi S, Matusali G, Colavita F, Farroni C, Cuzzi G, Cimini E, Tartaglia E, Vanini V, Prosperini L, Haggiag S, Galgani S, Quartuccio ME, Salmi A, Repele F, Altera AMG, Cristofanelli F, D'Abramo A, Bevilacqua N, Corpolongo A, Puro V, Vaia F, Capobianchi MR, Ippolito G, Nicastri E, Goletti D; INMI COVID-19 Vaccine Study Group. Tortorella C, et al. Neurology. 2022 Feb 1;98(5):e541-e554. doi: 10.1212/WNL.0000000000013108. Epub 2021 Nov 22. Neurology. 2022. PMID: 34810244 Free PMC article.
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S, De Pascale L, Matusali G, Mariotti D, Cozzi Lepri A, Gallì P, Pinnetti C, Gagliardini R, Mazzotta V, Mastrorosa I, Grisetti S, Colavita F, Cimini E, Grilli E, Bellagamba R, Lapa D, Sacchi A, Marani A, Cerini C, Candela C, Fusto M, Puro V, Castilletti C, Agrati C, Girardi E, Vaia F; HIV-VAC Study Group. Antinori A, et al. Clin Infect Dis. 2022 Aug 24;75(1):e552-e563. doi: 10.1093/cid/ciac238. Clin Infect Dis. 2022. PMID: 35366316 Free PMC article.
Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results.
Agrati C, Castilletti C, Battella S, Cimini E, Matusali G, Sommella A, Sacchi A, Colavita F, Contino AM, Bordoni V, Meschi S, Gramigna G, Barra F, Grassi G, Bordi L, Lapa D, Notari S, Casetti R, Bettini A, Francalancia M, Ciufoli F, Vergori A, Vita S, Gentile M, Raggioli A, Plazzi MM, Bacchieri A, Nicastri E, Antinori A, Milleri S, Lanini S, Colloca S, Girardi E, Camerini R, Ippolito G, Vaia F, Folgori A, Capone S. Agrati C, et al. Among authors: francalancia m. NPJ Vaccines. 2022 Sep 24;7(1):111. doi: 10.1038/s41541-022-00531-8. NPJ Vaccines. 2022. PMID: 36153335 Free PMC article.
Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine.
Agrati C, Castilletti C, Goletti D, Sacchi A, Bordoni V, Mariotti D, Notari S, Matusali G, Meschi S, Petrone L, Aiello A, Najafi Fard S, Farroni C, Colavita F, Lapa D, Leone S, Agresta A, Capobianchi M, Ippolito G, Vaia F, Puro V; INMI COVID-19 Vaccine Study Group. Agrati C, et al. Sci Rep. 2022 Apr 23;12(1):6687. doi: 10.1038/s41598-022-07741-z. Sci Rep. 2022. PMID: 35461335 Free PMC article.
Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
D'Abramo A, Vita S, Maffongelli G, Beccacece A, Agrati C, Cimini E, Colavita F, Giancola ML, Cavasio A, Nicastri E; Spallanzani COVID-19 Case Investigation Team. D'Abramo A, et al. Front Immunol. 2022 May 27;13:911339. doi: 10.3389/fimmu.2022.911339. eCollection 2022. Front Immunol. 2022. PMID: 35711444 Free PMC article.
22 results